Yan Wang1, Yuechang Yang1, Huijuan Wu2, Danmei Lan1, Ying Chen2, Zhongxin Zhao1. 1. Department of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai, China. 2. Sleep Center, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Abstract
STUDY OBJECTIVES: REM sleep behavior disorder (RBD) is a common manifestation of Parkinson disease (PD). In this study, we assessed the effects of rotigotine transdermal patch on RBD features in patients with PD. METHODS: In this prospective open-label study, eleven PD patients with untreated RBD were administered rotigotine patches for up to seven months to ameliorate their parkinsonism. The severities of their RBD symptoms before and after rotigotine therapy were evaluated through patient and bed partner interviews, a validated evaluation scale (REM sleep behavior disorder questionnaire-Hong Kong, RBDQ-HK), and blinded assessments based on video-polysomnographic (VPSG) measure. RESULTS: Rotigotine improved parkinsonism and subjective sleep quality in PD patients with RBD. The RBDQ-HK total score, especially the Factor 2 score, was decreased, which demonstrated that the subjective severity of RBD symptoms was improved after rotigotine treatment, especially the frequency and severity of abnormal RBD-related motor behaviors. The VPSG analyses showed that the total sleep time (TST) and stage 1% were increased and that the PLMS index was decreased. However, no differences in the RBD-related sleep measures were observed. CONCLUSIONS: The improved RBD symptoms and VPSG measures of PD patients in this study (TST, stage 1%, and PLMS index) suggest that, in PD, rotigotine may partially improve RBD-related symptoms. Rotigotine should be considered to be an optional drug for the treatment of RBD symptoms in PD.
STUDY OBJECTIVES:REM sleep behavior disorder (RBD) is a common manifestation of Parkinson disease (PD). In this study, we assessed the effects of rotigotine transdermal patch on RBD features in patients with PD. METHODS: In this prospective open-label study, eleven PDpatients with untreated RBD were administered rotigotine patches for up to seven months to ameliorate their parkinsonism. The severities of their RBD symptoms before and after rotigotine therapy were evaluated through patient and bed partner interviews, a validated evaluation scale (REM sleep behavior disorder questionnaire-Hong Kong, RBDQ-HK), and blinded assessments based on video-polysomnographic (VPSG) measure. RESULTS:Rotigotine improved parkinsonism and subjective sleep quality in PDpatients with RBD. The RBDQ-HK total score, especially the Factor 2 score, was decreased, which demonstrated that the subjective severity of RBD symptoms was improved after rotigotine treatment, especially the frequency and severity of abnormal RBD-related motor behaviors. The VPSG analyses showed that the total sleep time (TST) and stage 1% were increased and that the PLMS index was decreased. However, no differences in the RBD-related sleep measures were observed. CONCLUSIONS: The improved RBD symptoms and VPSG measures of PDpatients in this study (TST, stage 1%, and PLMS index) suggest that, in PD, rotigotine may partially improve RBD-related symptoms. Rotigotine should be considered to be an optional drug for the treatment of RBD symptoms in PD.
Authors: Jacques Montplaisir; Jean-Francois Gagnon; Maria Livia Fantini; Ronald B Postuma; Yves Dauvilliers; Alex Desautels; Sylvie Rompré; Jean Paquet Journal: Mov Disord Date: 2010-10-15 Impact factor: 10.338
Authors: Ilonka Eisensehr; Reiner Linke; Klaus Tatsch; Bita Kharraz; Josef F Gildehaus; Christian T Wetter; Claudia Trenkwalder; Johannes Schwarz; Soheyl Noachtar Journal: Sleep Date: 2003-08-01 Impact factor: 5.849
Authors: Stuart J McCarter; Christopher L Boswell; Erik K St Louis; Lucas G Dueffert; Nancy Slocumb; Bradley F Boeve; Michael H Silber; Eric J Olson; Maja Tippmann-Peikert Journal: Sleep Med Date: 2013-01-23 Impact factor: 3.492
Authors: Yves Dauvilliers; Carlos H Schenck; Ronald B Postuma; Alex Iranzo; Pierre-Herve Luppi; Giuseppe Plazzi; Jacques Montplaisir; Bradley Boeve Journal: Nat Rev Dis Primers Date: 2018-08-30 Impact factor: 52.329
Authors: Miguel Rosa-Grilo; Mubasher A Qamar; Raquel N Taddei; Javier Pagonabarraga; Jaime Kulisevsky; Anna Sauerbier; K Ray Chaudhuri Journal: NPJ Parkinsons Dis Date: 2017-09-05